Ledipasvir (GS-5885) / Gilead 
Welcome,         Profile    Billing    Logout  
 17 Diseases   0 Trials   0 Trials   96 News 
  • ||||||||||  ombitasvir (ABT-267) / AbbVie, Ledipasvir (GS-5885) / Gilead, elbasvir (MK-8742) / Merck (MSD)
    Journal:  In silico Antivirus Repurposing and its Modification to Organoselenium Compounds as SARS-CoV-2 Spike Inhibitors. (Pubmed Central) -  Jun 6, 2023   
    The best-modified ligand was chosen by analyzing the ADME-Tox property, RMSD value and binding energy value. <b></b> The best three unmodified ligands, Ombitasvir, Elbasvir and Ledipasvir, have a binding energy value of -15.8065, -15.3842 and -15.1255 kcal mol<sup>1</sup>, respectively and the best three modified ligands ModL1, ModL2 and ModL3 has a binding value of -15.6716, -13.9489 and -13.2951 kcal mol<sup>1</sup>, respectively with an RMSD value of 1.7109
  • ||||||||||  Ledipasvir (GS-5885) / Gilead, Tasigna (nilotinib) / Novartis, Inhibikase
    Journal:  Wolbachia Ferrochelatase as a potential drug target against filarial infections. (Pubmed Central) -  May 22, 2023   
    This prevents the worm from receiving the heme molecule from Wolbachia for their growth and survival, resulting in their death. This study which involved targeting enzymes in biosynthetic pathways of the parasitic worms' endosymbiont (Wolbachia), has proven to be an alternative therapeutic option leading to the discovery of new drugs, which will help facilitate the elimination of parasitic infections.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    Journal:  Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization. (Pubmed Central) -  Nov 25, 2022   
    Compared to 4a, the 4d(C5A)-13m virus was more sensitive to neutralizing monoclonal antibodies AR3A and AR5A, as well as 4a and 4d patient plasma antibodies. In conclusion, we developed the first genotype 4d infectious culture system enabling DAA efficacy testing and antibody neutralization assessment critical to optimization of DAA treatments in the clinic and for vaccine design to combat the HCV epidemic.
  • ||||||||||  remdesivir / Generic mfg.
    Journal:  Effectiveness of Remdesivir in Comparison with Five Approved Antiviral Drugs for Inhibition of RdRp in Combat with SARS-CoV-2. (Pubmed Central) -  Oct 4, 2022   
    Also, the results show that the number of H-bonds and contacts and ∆G interactions between the protein and ligand in the Remdesivir complex is less than those of other complexes. According to the given data which shows the tendency of binding with RdRp for Paritaprevir, Simeprevir, Glecaprevir, and Ledipasvir and Elbasvir is more than Remdesivir and due to the fact that these five drugs have a high tendency to bind to other targets in the SARS-CoV-2, the use of Remdesivir as an antiviral drug in the treatment of COVID-19 should be considered more sensitively.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Ledipasvir (GS-5885) / Gilead, elbasvir (MK-8742) / Merck (MSD)
    Journal:  Applying polypharmacology approach for drug repurposing for SARS-CoV2. (Pubmed Central) -  May 3, 2022   
    Four drugs namely venetoclax, tirilazad, acetyldigitoxin, and ledipasvir have been selected as potential candidates. The online version contains supplementary material available at 10.1007/s12039-022-02046-0.
  • ||||||||||  ParvOryx (parvovirus H-1) / Oryx
    Identification of an Antiviral Drug as a Novel Potentiator of H-1PV-Mediated Oncolysis (Poster Board Number: Tu-192; Hall D) -  Apr 20, 2022 - Abstract #ASGCT2022ASGCT_715;    
    We are currently validating these pathways by independent methods, as well as investigating the effect of ledipasvir on H-1PV replication. Our data demonstrates for the first time that ledipasvir is able to potentiate the oncotoxicity of H-1PV and is a promising candidate for combination therapy in the clinics.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    HCV-associated fibrosing cholestatic hepatitis (FCH) resolved by DAA treatment in a HIV/HCV-coninfected patient (eLibrary) -  Sep 18, 2021 - Abstract #EACS2021EACS_864;    
    After referral to our HIV centre we started cotrimoxazole for pneumocystis jirovecii pneumonia, amphotericin B for esophageal candidiasis, valganciclovir for CMV-viremia and ART...After initiation of DAA (sofobuvir/ledipasvir/ribavirin) for 24 weeks, the HCV-replication decreased in parallel with GGT...Disease Course . Liver histology CK7 staining
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    HCV-associated fibrosing cholestatic hepatitis (FCH) resolved by DAA treatment in a HIV/HCV-coninfected patient (eLibrary) -  Sep 18, 2021 - Abstract #EACS2021EACS_397;    
    After referral to our HIV centre we started cotrimoxazole for pneumocystis jirovecii pneumonia, amphotericin B for esophageal candidiasis, valganciclovir for CMV-viremia and ART...After initiation of DAA (sofobuvir/ledipasvir/ribavirin) for 24 weeks, the HCV-replication decreased in parallel with GGT...Disease Course . Liver histology CK7 staining
  • ||||||||||  pibrentasvir (ABT-530) / AbbVie, Ledipasvir (GS-5885) / Gilead
    Clinical, Journal:  Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study. (Pubmed Central) -  Aug 13, 2021   
    The stabilities of these three promising candidates in complex with ABCG2 transporter were demonstrated by their energetics and structural analyses throughout the 100 ns MD simulations. The current study throws new light on pibrentasvir, venetoclax, and ledipasvir as curative options for multidrug resistant cancers by inhibiting ABCG2 transporter.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    Preclinical, Journal:  Galactosylated chitosan coated liposomes of ledipasvir for liver targeting: Chemical synthesis, Statistical optimization, In-vitro and In-vivo evaluation. (Pubmed Central) -  Jun 22, 2021   
    The galactosylated chitosan coated liposomes had particle size of 218.2 nm ± 7.21, zeta potential of 27.15 mV ± 1.76, polydispersity index of 0.278 ± 0.055 and entrapment efficiency % of 54.63 % ± 0.05 respectively. The pharmacokinetic study revealed a significant increase in the liver peak concentration (C) and the area under liver concentration versus time curve AUC and significant prolongation in the liver terminal half life (t½) and mean residence time (MRT) in comparison to the oral dispersion of ledipasvir with values of 11400 ng/g, 88855 ng*h/g, 32.00 h and 18.11 h respectively.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    FDA event, Journal:  Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. (Pubmed Central) -  May 22, 2021   
    Notably, both remdesivir (half-maximal effective concentration (EC50) 6.6 μM, 50% cytotoxicity concentration (CC) > 100 µM, selectivity index (SI) = 15) and ledipasvir (EC50 34.6 μM, CC > 100 µM, SI > 2.9) exerted antiviral action. This study highlights the use of direct-acting antiviral drugs, alone or in combination, for better treatments of COVID-19.
  • ||||||||||  Invirase (saquinavir) / Roche, velpatasvir (GS-5816) / Gilead, Ledipasvir (GS-5885) / Gilead
    Journal:  Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. (Pubmed Central) -  Nov 24, 2020   
    Docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area (MM/GBSA) studies indicated that dimeric M most significantly impacts binding affinity tendency compared with the monomeric state, which suggests that dimeric state is most useful when performing studies aimed at identifying drugs targeting M. In this study, we extend previous research by performing docking and MD simulation studies coupled with an MM/GBSA approach to assess binding of dimeric SARS-CoV2 M to 12 FDA-approved drugs (darunavir, indinavir, saquinavir, tipranavir, diosmin, hesperidin, rutin, raltegravir, velpatasvir, ledipasvir, rosuvastatin, and bortezomib), which were identified as the best candidates for the treatment of COVID-19 in some previous dockings studies involving monomeric SARS-CoV2 M. This analysis identified saquinavir as a potent inhibitor of dimeric SARS-CoV2 M; therefore, the compound may have clinical utility against COVID-19. Graphical abstract.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead, Daklinza (daclatasvir) / BMS
    [VIRTUAL] EFFICACY, TOLERABILITY AND COMPLIANCE OF DIRECTLY ACTING ANTIVIRALS IN PATIENTS WITH HEPATITIS C AND HIV CO-INFECTION: REAL LIFE EXPERIENCE FROM A TERTIARY CARE CENTER IN INDIA () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_908;    
    Dose modifications of DAAs (Daclatasvir and Ledipasvir) were done depending on interactions with concurrent ART regimen...ART regimen comprised of a combination of Tenofovir(T), Lamivudine(L), Efavirenz (E), Nevirapine (N), and/or Zidovudine (Z) at standard dosage and modifications as applicable to individual patients [TLE: 63(82.9%), ZLN:11(14.5%) and ZLE: 2(2.6%)]... HCV-HIV coinfected patients demonstrate excellent SVR12 rates and tolerability with available DAAs; however, dismal proportion of these patients seek and complete their treatment, outlining the need of better counselling, screening and outreach programs among this high-risk group of patients.
  • ||||||||||  glecaprevir (ABT-493) / AbbVie, Ledipasvir (GS-5885) / Gilead, paritaprevir/ritonavir (ABT-450/r) / AbbVie
    Journal:  Drug repurposing using computational methods to identify therapeutic options for COVID-19. (Pubmed Central) -  Aug 26, 2020   
    According to the results, glecaprevir, paritaprevir, simeprevir, ledipasvir, glycyrrhizic acid, TMC-310911, and hesperidin showed highly favorably free binding energies with all tested target proteins. The above-mentioned drugs can be regarded as candidates to treat COVID-19 infections, but further study on the efficiency of these drugs is also necessary.
  • ||||||||||  Preclinical, Journal:  Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices. (Pubmed Central) -  Aug 20, 2020   
    Lopinavir, ritonavir, saquinavir, atazanavir, maraviroc, ledipasvir, and daclatasvir inhibited the efflux of a model ABCB1 substrate, rhodamine 123 (RHD123), in Caco-2 cells and rat-derived PCIS...Abacavir, zidovudine, tenofovir disoproxil fumarate, etravirine, and rilpivirine did not inhibit intestinal ABCB1...Our data help clarify the molecular mechanisms responsible for reported increases in the bioavailability of ABCB1 substrates including antivirals and drugs prescribed to treat co-morbidity. These results could help guide the selection of combination pharmacotherapies and/or suitable dosing schemes for patients infected with HIV and/or HCV.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    TIME TO DAA TREATMENT FOR HCV DISFAVORS PATIENTS WITH HCV/HIV CO-INFECTION: AN URBAN TERTIARY CLINIC EXPERIENCE () -  May 4, 2020 - Abstract #DDW2020DDW_7072;    
    Potential barriers that may delay time to DAA treatment, psychiatric and alcohol and substance use disorders and CKD, did not negatively impact time to DAA treatment; and patients with HIV/HCV co-infection were stably on ART. Findings highlight a need for future studies to examine and ascertain the reasons why time to DAA treatment disfavors patients with HIV/HCV co-infection—who are receiving services and care from the same clinic and providers as patients with HCV mono-infection.
  • ||||||||||  Ledipasvir (GS-5885) / Gilead
    HCV RESISTANCE PATTERNS IN A WORLDWIDE NETWORK OF COHORTS OF GT-3a INFECTED PATIENTS (Sheraton Boston Hotel, Constitution Ballroom) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2166;    
    The frequency of the co-occurrence of Y93H with another RAS at position 30 (A30S, A30K) depended on the treatment regimen received (first versus last-generations DAAs). Multiple NS3 and NS5A RASs can challenge retreatment with last-generation NS5A inhibitors.